Amicus Therapeutics Inc. priced an underwritten offering with gross proceeds expected to be $225 million.
Arena Pharmaceuticals Inc. priced an underwritten public offering of 6.25 million shares of its common stock at $24 each for gross proceeds of $150 million.
Carmell Therapeutics Inc. closed a $4 million series B financing.
Egalet Corp. closed its underwritten public offering for expected gross proceeds of approximately $30 million.
Kala Pharmaceuticals Inc. filed to offer to sell 6 million shares of its common stock, priced between $14 and $16 per share, in an IPO.
Kitov Pharmaceuticals Holdings Ltd. issued 2.43 million American depositary shares (ADS) at $1.45 per ADS to institutional and other investors in a registered direct offering.
Zealand Pharma A/S filed with the SEC to raise up to $86 million in a U.S. IPO.
Abzena plc signed a licensing agreement and a master services and clinical supply agreement with OBI Pharma, who will use its site-specific Thiobridge antibody-drug conjugate (ADC) linker technology to develop its ADC, OBI-999, and a series of further ADCs as potential treatments for cancer.
Alimera Sciences Inc. secured the rights to pursue posterior uveitis, a secondary indication for Iluvien (fluocinolone acetonide), in the EU, the Middle East and Africa in a second amended collaboration agreement with Psivida US Inc., a subsidiary of Psivida Corp.
Applied Immunotherapeutics Inc. and The Feinstein Institute for Medical Research at Northwell Health inked a deal in which Applied licensed discoveries in treating inflammation, as well as specific antibodies and drug candidates.
Capricor Therapeutics Inc. said Janssen Biotech Inc., a unit of Johnson & Johnson, decided not to exercise its option to license CAP-1002 (allogeneic cardiosphere-derived cells).
Daiichi Sankyo Co. Ltd., Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi with the option to receive the exclusive rights to a new lead compound for the treatment of cancer that will be developed at the Lead Discovery Center.
Erytech Pharma SA entered a collaboration with Queen's University in Kingston, Ontario, to advance the preclinical development of the company's eryminase program for the treatment of arginase-1 deficiency.
Inmed Pharmaceuticals Inc. entered a research and development collaboration with Atera SAS, which specializes in the development of advanced human tissue models.
Medimmune and Washington University School of Medicine in St. Louis entered an oncology research and clinical alliance aimed at developing neoantigen vaccines for use in combination with checkpoint inhibitors and other cancer immunotherapy agents.
Race Oncology Ltd., with Targimmune Therapeutics AG, formed Race Immunotherapeutics, a joint venture focusing on cancer therapies based on combining Bisantrene with Targimmune's CTPIC targeted cancer therapy technology.
Sanofi SA said it will acquire Protein Sciences Inc. for an up-front payment of $650 million and up to $100 million linked to certain milestones.
. . . And More
Emmaus Medical Inc.'s pharmaceutical-grade L-glutamine received FDA approval as a treatment for sickle cell disease.
G20 leaders announced the formation of the Global Antimicrobial Resistance Collaboration Hub (GAMRCH), which will act to coordinate various other international efforts, to invigorate research and to promote investment across all stages of antimicrobial development.
India's Central Drugs Standard Control Organization (CDSCO) has been streamlining regulations to standardize its rules on the market for pharmaceuticals.
Neothetics Inc. plans to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow it to maximize shareholder value from its remaining assets and cash resources.
Ocular Therapeutix Inc. received a complete response letter from the FDA regarding its NDA for Dextenza (dexamethasone insert) 0.4 mg for the treatment of ocular pain following ophthalmic surgery.
Pfizer Inc. said the FDA accepted its supplemental NDA for Xeljanz (tofacitinib citrate) for the treatment of adult patients with moderately to severely active ulcerative colitis. The PDUFA date is in March 2018.
Principia Biopharma Inc. said PRN-1008, a reversible covalent BTK inhibitor, was granted orphan designation by the FDA for pemphigus vulgaris.
The FDA's Oncologic Drugs Advisory Committee voted unanimously in support of Novartis AG's CTL-019 (tisagenlecleucel), a CAR T immunotherapy.